Loading…
Elutia Inc. is projected to rise to $1.13 by 2027, a +17% move from its current price of $0.963. ELUT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.9347 | $0.9631 | $0.9923 | +0.01% |
| Jul 13 | $0.9233 | $0.9632 | $1.00 | +0.02% |
| Jul 14 | $0.9146 | $0.9632 | $1.01 | +0.03% |
| Jul 15 | $0.9074 | $0.9633 | $1.02 | +0.03% |
| Jul 16 | $0.901 | $0.9634 | $1.03 | +0.04% |
| Jul 17 | $0.8954 | $0.9635 | $1.04 | +0.05% |
| Jul 18 | $0.8902 | $0.9636 | $1.04 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8902 | $0.9636 | $1.04 | +0.06% |
| Week 2 | $0.862 | $0.9641 | $1.08 | +0.12% |
| Week 3 | $0.8411 | $0.9647 | $1.11 | +0.18% |
| Week 4 | $0.8239 | $0.9653 | $1.13 | +0.23% |
| Week 5 | $0.8091 | $0.9658 | $1.15 | +0.29% |
| Week 6 | $0.796 | $0.9664 | $1.17 | +0.35% |
| Week 7 | $0.7842 | $0.9669 | $1.19 | +0.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Elutia Inc. is a commercial-stage healthcare company focused on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Its lead development programs include NXT-41 and NXT-41x, designed as biologic scaffolds combined with local antibiotic delivery. Elutia provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction, and ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature.
The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc.
in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Elutia Inc. (ELUT) is priced at $0.96 per share, with a $42.44M market cap and a rank of 4647. The current price and market position set the baseline for the long-range forecast. The forecast envisions growth through 2030 and beyond, with the average price rising to $1.51 by 2030 and to $4.79 on average by 2050, while maximums reach higher targets along the way.
The outlook suggests notable upside in the later years, with substantial optionality reflected in the higher end of the forecast.
A major floor 17.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 20.5% above — a clean break opens room to run.
A major ceiling 29.4% above — clearing it would confirm fresh momentum.
Key ELUT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELUT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9586 | Buy | $0.9608 | Buy |
| MA 10 | $0.9605 | Buy | $0.9639 | Sell |
| MA 20 | $0.9725 | Sell | $0.9788 | Sell |
| MA 50 | $1.02 | Sell | $1.01 | Sell |
| MA 100 | $1.07 | Sell | $1.03 | Sell |
| MA 200 | $0.94 | Buy | $1.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.49 | Neutral |
| Stoch RSI (14) | 55.07 | Neutral |
| CCI (20) | -27.31 | Neutral |
| Williams %R (14) | -68.37 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -6.50 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 31.63 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 41.03 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.96 | Sell |
| ADX (14) | 10.99 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical picture is NEUTRAL. The RSI14 is 50, and the 50-day simple moving average is $1.03 while the 200-day simple moving average is $0.942. The stock shows a defined support at $0.932 and a resistance at $1.16. The 30-day price range spans from $0.776 to $1.19, indicating modest volatility in the recent period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.614 | $0.963 | $1.29 | 0% | Neutral | |
| $0.8888 | $1.13 | $1.52 | +17% | Neutral | |
| $1.01 | $1.32 | $1.84 | +37% | Bullish | |
| $1.03 | $1.38 | $1.99 | +43% | Bullish | |
| $1.07 | $1.46 | $2.17 | +52% | Bullish | |
| $1.02 | $1.43 | $2.18 | +49% | Bullish | |
| $0.9357 | $1.34 | $2.07 | +39% | Bullish | |
| $1.05 | $1.52 | $2.40 | +58% | Bullish | |
| $1.18 | $1.74 | $2.80 | +81% | Bullish | |
| $1.29 | $1.94 | $3.16 | +102% | Bullish | |
| $1.30 | $2.11 | $3.68 | +119% | Bullish | |
| $2.42 | $4.49 | $8.59 | +366% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.614 | $0.963 | $1.12 | +0.00% |
| August 2026 | $0.7806 | $0.9239 | $1.12 | -4.06% |
| September 2026 | $0.8136 | $0.9704 | $1.20 | +5.03% |
| October 2026 | $0.8243 | $0.9896 | $1.23 | +1.99% |
| November 2026 | $0.8133 | $0.9818 | $1.23 | -0.79% |
| December 2026 | $0.8412 | $1.02 | $1.29 | +3.98% |
Click any year to see its month-by-month ELUT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ELUT is projected to trade between $0.614 and $1.29, averaging $0.963 — a potential gain of 0% from today's $0.963. A consolidation phase looks the most probable path here.
Elutia Inc.'s 2027 outlook centres on $1.13, within a $0.8888 to $1.52 range. That is up +17% on the projected 2026 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2028, ELUT could reach as high as $1.84, with a base case around $1.32 and support toward $1.01 — roughly +37% from $0.963. Buyers look set to stay in control over this stretch.
Expect ELUT to range from $1.03 to $1.99 through 2029. The $1.38 average target implies a +43% move from current prices. That is up +5% on the projected 2028 average. Momentum favours further upside here.
The ELUT price prediction for 2030 points to an average of $1.46 (low $1.07, high $2.17) — a potential gain of +52% on today's $0.963. Buyers look set to stay in control over this stretch.
In 2031, ELUT is projected to trade between $1.02 and $2.18, averaging $1.43 — a potential gain of +49% from today's $0.963. That is -2% versus the projected 2030 average. Momentum favours further upside here.
Elutia Inc.'s 2032 outlook centres on $1.34, within a $0.9357 to $2.07 range. That is -7% versus the projected 2031 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ELUT could reach as high as $2.40, with a base case around $1.52 and support toward $1.05 — roughly +58% from $0.963. Momentum favours further upside here.
Expect ELUT to range from $1.18 to $2.80 through 2034. The $1.74 average target implies a +81% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ELUT price prediction for 2035 points to an average of $1.94 (low $1.29, high $3.16) — a potential gain of +102% on today's $0.963. Momentum favours further upside here.
In 2040, ELUT is projected to trade between $1.30 and $3.68, averaging $2.11 — a potential gain of +119% from today's $0.963. That is up +9% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Elutia Inc.'s 2050 outlook centres on $4.49, within a $2.42 to $8.59 range. That is up +113% on the projected 2040 average. That marks a +366% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ELUT today (≈ 1,038.421599 ELUT) could be worth
$4,660.59
+$3,660.59 (+366%) by 2050 · US Dollar
Based on the average projected ELUT price of $4.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELUTwould be worth at today's price.
$1,000 invested in ELUT on Jul 10, 2025 (≈ 408.163257 ELUT) would be worth
$393.06
-$606.94 (-60.7%) today · 0.39× · US Dollar
Based on a ELUT entry price of $2.45 vs. today's $0.963.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.932 | $1,033.26 | +3.3% |
| 1 month ago | $1.04 | $925.96 | -7.4% |
| 3 months ago | $1.13 | $852.21 | -14.8% |
| 6 months ago | $0.689 | $1,397.68 | +39.8% |
| 1 year ago | $2.45 | $393.06 | -60.7% |
| All time (5.0y) ago | $7.7 | $125.06 | -87.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELUT forecast.
Our base-case forecast reaches $1.90 around 2035.
Implied market cap at $1.90: $84M
The multi-year forecast points to a bullish trajectory, with the average price rising from $0.96 in 2026 to $1.51 in 2030. By 2030 the average is $1.51 with a 57.1% ROI; the 2040 projection shows an average of $2.21 and a 130.3% ROI; and by 2050 the average is $4.79 with a 398.6% ROI. The forecast also indicates progressively higher maximums, including $2.27 in 2030, $3.95 in 2040 and $9.45 in 2050.
Sentiment shifts to BULLISH in the later years, underscoring the expected upside, though these are estimates, not guarantees, and risks remain.
Tap a question to reveal the answer.
2030 average price $1.51; min $1.08; max $2.27; ROI 57.1%; sentiment BULLISH.
Forecast shows a bullish trajectory with steady gains toward 2030–2050, including 2030 avg $1.51 and 2050 avg $4.79 with ROI up to 398.6%; these are estimates, not guarantees.
Yes. Forecast maximums reach $3.00 by 2034, $3.41 by 2035, $3.95 by 2040, and as high as $9.45 by 2050.
Current price $0.96; market cap $42.44M; rank 4647.
The 30-day range is $0.776 to $1.19 with RSI 50, SMA50 $1.03, SMA200 $0.942, support $0.932 and resistance $1.16; sentiment NEUTRAL.
Elutia Inc. Community Discussion
0Share your Elutia Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.